GSK’s RSV Vaccine Shows Real-World Efficacy in Reducing Cardiovascular and Respiratory Risks — GSK plc

Event summary

GSK’s AREXVY vaccine demonstrated a 75.6% effectiveness in preventing RSV-related hospitalizations in adults aged ≥60 years, per a US study with over 2.5 million participants.
The vaccine showed a 63.1% effectiveness against major adverse cardiovascular events (MACE) during RSV-related hospitalization.
Exploratory endpoints indicated 74.4% and 61.6% effectiveness in preventing severe COPD and asthma flare-ups, respectively.
A separate Danish study found 100% effectiveness in preventing RSV-related hospitalizations among COPD patients aged ≥60 years.

The big picture

GSK’s data underscores the growing importance of RSV vaccination in preventing severe outcomes beyond just respiratory infections, particularly in older adults with comorbidities. The findings position AREXVY as a critical tool in reducing healthcare burdens during winter months, aligning with broader trends toward preventive care in aging populations.

What we're watching

Market Adoption: The pace at which healthcare systems and high-risk patients adopt AREXVY following these real-world efficacy findings.
Competitive Dynamics: Whether GSK can maintain its leadership position in RSV prevention as competitors develop similar vaccines.
Regulatory Impact: How these results may influence regulatory approvals and recommendations for broader use of AREXVY in younger or lower-risk populations.